Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01370733 · ClinicalTrials.gov registry record · Phase 3
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
A Phase 3 study of Major Depressive Disorder, sponsored by Wave Neuroscience.
- Completed
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
- 18
- Study locations
NCT01370733 is a Phase 3 study of Major Depressive Disorder that has completed, run by Wave Neuroscience. The registered enrollment target is 202 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (46% lower). The trial reports 18 study locations across 13 states.
The verdict
NCT01370733, a Phase 3 study of Major Depressive Disorder, has completed, sponsored by Wave Neuroscience.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Major Depressive Disorder. This is a multicenter study in which subjects will be randomized to receive treatment 5 days per week for 6 weeks. Subjects who complete 6 weeks of double-blind treatment may be eligible to receive up to four weeks of open label sTMS therapy or antidepressant medications during the follow-up phase of the study. Follow-up evaluation visits will be conducted during those four weeks, with the frequency of the visits determined by the treatment choice during that timeframe.
Conditions Studied
Interventions
- DEVICE SHAM
- DEVICE NEST-1 (NeoSync EEG Synchronized TMS)
Study Locations (18)
California
- UCLA Depression Research & Clinic Program - Los Angeles
- UCSD Medical Center - San Diego
- UCLA-Harbor - Torrance
North Carolina
- Duke University Brain Stimulation and Neurophysiology Center - Durham
- Wake Forest University Medical Center - Winston-Salem
Pennsylvania
- University of Pennsylvania - Philadelphia
- Mood Disorders Treatment Research Program University of Pittsburgh-Western Psychiatric Institute and Clinic - Pittsburgh
Texas
- UT Southwestern Medical Center - Dallas
- R/D Clinical Research - Lake Jackson
Connecticut
- Hartford Hospital Institute of Living - Hartford
Illinois
- TMS Specialists Chicago - Chicago
Maryland
- Sheppard Pratt Health System - Baltimore
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01370733
The ClinicalTrials.gov registry entry for NCT01370733 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (46% lower). The listed sponsor is Wave Neuroscience, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which SHAM is the first listed.
NCT01370733 reports 18 study locations spanning 13 distinct geographic areas - top geographies include California, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01370733 about?
NCT01370733 is a clinical study titled "Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder". This study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Major Depressive Disorder. This is a multicenter study in which subjects will be randomized to receive treatment 5...
What is the current status of trial NCT01370733?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2012-05. Estimated completion is 2013-09.
What conditions does trial NCT01370733 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT01370733?
The interventions under investigation include: SHAM (DEVICE), NEST-1 (NeoSync EEG Synchronized TMS) (DEVICE).
Who is sponsoring clinical trial NCT01370733?
This trial is sponsored by Wave Neuroscience, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01370733 being conducted?
This trial has 18 study locations across California, Connecticut, Illinois, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.